Join us in a new, exciting future for Indivumed
On April 1, 2023, Indivumed and Crown Bioscience completed the acquisition of IndivuServ, Indivumed’s services business. This results in two separate companies: Indivumed Therapeutics and Indivumed Services, a wholly owned subsidiary of Crown Bioscience.
The level of high-quality services and research partnerships that Indivumed’s customers can expect in the new constellation will be enhanced. Drawing on their unique strengths, both companies will join forces to create a new precision oncology powerhouse.
Please select the company that is the most suitable partner for your needs.
Indivumed Services a Crown Bioscience Company
Comprehensive Biobank products, laboratory services, and research partnerships.
• Biomarker Discovery and Validation
• Drug Profiling
AI-assisted advanced analytics for novel discoveries
in multi-omics-based oncology R&D.
nRavel® Rx: Target Identification and Validation,
In-silico and In-vitro
• Patient-Based Target Discovery
• Patient-Based Cellular Models
nRavel® Dx: Optimized Clinical Study Design
• Tailor-Made Study Design for Your Target